Strides Arcolab plans to buy out Australian venture Ascent

17 Mar 2010 Evaluate

Generic drugs maker Strides Arcolab Ltd has informally offered to buy the remaining 43 per cent stake in its Australian venture, Ascent Pharmahealth Ltd. The final outcome is expected to be known in the next 90 days.

 

Ascent, now listed on the Australian Stock Exchange, would be de-listed. The Australian company has been valued at $100 million. For the 43 per cent share it plans to buy, Strides would make a cash offer of Australian $35 million (nearly Rs 145 crore at current exchange rates), proposing to buy the stake at a premium rate of $0.35 per share.

 

The Bangalore-based company plans to include Ascent's founder-CEO, Mr Dennis Bastas, as an equity participant in its formal offer and also retain the executive management team. The money for the acquisition would come both from company resources and debt.

 

The attraction in Ascent apparently lies in its large complementary generic medicine chest, besides prescribed and freely sold (OTC) skin care products. It is the fourth largest non-patent drug maker in that country. The plan, if it came through, would make Strides the largest Indian company there. Early this month, Strides bought back its Brazilian facility for $75 million from Aspen Pharmacare of South Africa.

crackcrack

Strides Pharma Scien Share Price

875.35 46.70 (5.64%)
15-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1528.20
Dr. Reddys Lab 5872.35
Cipla 1405.95
Zydus Lifesciences 997.45
Lupin 1638.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.